You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
The Authors' reply
  1. Guy E Boeckxstaens1,2,
  2. Tamira Klooker2
  1. 1Department of Gastroenterology, University Hospital of Leuven/Catholic University of Leuven, Leuven, Belgium
  2. 2Academic Medical Center, Amsterdam, The Netherlands
  1. Correspondence to Guy E Boeckxstaens, Department of Gastroenterology, University Hospital of Leuven/Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium; guy.boeckxstaens{at}med.kuleuven.be

https://doi.org/10.1136/gut.2010.226217

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Authors' reply We would like to thank Dr O'Sullivan for her positive comment1 on our paper recently published in Gut.2 We agree that the exact mechanism of action of ketotifen, either through mast cell stabilisation or H1 receptor blockade, needs further study. We tend to disagree, however, that we may have missed differences between patients with irritable bowel syndrome (IBS) and healthy subjects by …

    View Full Text

    Footnotes

    • Linked articles 225078.

    • Competing interests None.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; not externally peer reviewed.

    Linked Articles